Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2025 Shareholder and Analyst Conference Call. I will now turn the call over to Troy Wichterman, Chief Financial Officer of BioLife Solutions. Please go ahead.

Thank you, operator. Good afternoon, everyone, and thank you for joining the BioLife Solutions 2025 Third Quarter Earnings Conference Call. On the call with me today is Roderick de Greef, CEO and Chairman of the Board. We will cover business highlights and financial performance for the quarter and provide an update for our increased 2025 revenue guidance as adjusted for the sale of our evo Cold Chain product line. Earlier today, we issued a press release announcing our financial results and operational highlights for the third quarter of 2025, which is available at biolifesolutions.com. As a reminder, during this call, we will make forward-looking statements. These statements are subject to risks and uncertainties that can be found in our SEC filings. These statements speak only as of the date given, and we undertake no obligation to update them. We will also speak to non-GAAP or adjusted results. Reconciliations of GAAP to non-GAAP or adjusted financial metrics are included in the press release we issued this afternoon. Now I'd like to turn the call over to Rod de Greef, Chairman and CEO of BioLife.

Thanks, Troy. Good afternoon, and thank you for joining us for BioLife's Third Quarter 2025 Conference Call. We delivered another strong quarter, and we are raising our full year 2025 guidance as our team continues to execute and build on the momentum we've seen develop over recent quarters. On the top line, cell processing revenue increased 33% year-over-year, driving a 31% increase in total revenue for the quarter. This growth reflects sustained strength across our biopreservation media franchise and broader cell processing portfolio. Importantly, the mix of higher-margin recurring revenue continues to translate into improved profitability with adjusted EBITDA margin expanding 500 basis points year-over-year to 28%. This demonstrates that the operating leverage inherent in our business model is flowing through to the bottom line, driven by the benefits of our streamlined operations and focused product portfolio. In early October, we announced the sale of our evo Cold Chain logistics product line for approximately $25 million in cash. This transaction further strengthens our balance sheet, bringing cash and marketable securities to approximately $125 million. Strategically, the sale allows us to focus entirely on what is now a fully optimized portfolio, which is aligned with our core competencies and operational strengths, advancing our transformation into a leading pure-play cell processing company. Over the last 2 years, our actions have reshaped BioLife into a more focused, high-margin enterprise, positioning us to deliver sustainable growth and expanding profitability for the balance of 2025 and beyond, both from continued organic growth and potentially inorganically through the disciplined allocation of capital. Looking at the third quarter more closely, cell processing revenue reached $25.4 million, a 33% year-over-year increase, driven by strong growth across our BPM franchise and our broader cell processing tools portfolio. It's important to note that at the request of a commercial customer, we shipped $1.3 million of BPM product in the third quarter that was originally scheduled to ship in Q4. Adjusting for this timing-related pull forward, year-over-year cell processing revenue for Q3 would have come in at 26% and total revenue at 25%. Excluding the early shipment, BPM products represented more than 80% of total cell processing revenue, and our top 20 BPM customers continue to account for approximately 80% of BPM revenue, providing us with the benefit of increased visibility into this critical part of our business. These metrics are consistent with previous quarters and underscore the stability of our recurring revenue base. Staying focused on our BPM revenue, our direct versus distributor mix shifted to approximately 70-30 compared to our historical 60-40 split. This transition reflects continued momentum from our commercial customers, which accounted for nearly 50% of BPM revenue, driving a higher proportion of direct sales relative to distribution. Looking ahead, we expect that our existing commercial customers, together with those advancing late-stage clinical programs, will remain key drivers of future growth into next year and beyond, and that the commercial share of our BPM revenue will continue to increase over time. This increased mix of late-stage and commercial customers further highlights the resilience and consistency inherent in our model. This momentum within our BPM customer base is reinforced by the continued breadth and depth of our presence across the CGT landscape. At the end of the third quarter, our BPM products were embedded in 16 approved therapies and utilized in more than 250 relevant commercially sponsored CGT clinical trials in the U.S., representing over a 70% share. Notably, this includes more than 30 Phase III trials where our share is nearly 80%, underscoring BioLife's position as the default partner for later-stage clinical programs where success rates are higher and the path to commercial revenue is more clearly defined. Building on this market leadership, we continue to focus on expanding our role within these customer programs beyond biopreservation media. The sales and marketing team remains highly focused on the significant longer-term cross-sell opportunity in front of us to drive adoption of our other cell processing tools across our marquee BPM customer base. As I've previously stated, this opportunity has the potential to increase our revenue per patient dose by 2x to 3x compared to our BPM products alone as customers adopt additional components of our offering. We look forward to sharing progress on this front on future calls. As we look beyond the near term, our focus remains on the broader market dynamics shaping demand for cell processing solutions, particularly the continued expansion of patient access to cell therapies as well as expectations of additional unique approvals, geographic expansions, and new indications for existing approved therapies. Because our biopreservation media is embedded in nearly all approved cell therapies and nearly 80% of late-stage clinical trials, we have clearer visibility and predictability into future demand trends. More than half our BPM revenue comes from established commercial customers and late-stage programs, segments that are growing and less affected by early-stage volatility in the broader CGT landscape. In short, as patient access expands and new therapies are approved over time, BioLife will continue to grow with that dynamic, leveraging our market-leading position and trusted customer relationships to capture durable recurring revenue growth. Finally, given the results through the first 9 months of the year and our visibility into Q4 at this point, we're raising our full year cell processing revenue guidance, which was $91 million to $93 million, to $93 million to $94 million, representing a 26% to 28% year-over-year growth rate. Total revenue guidance when adjusted for the sale of evo is expected to come in at $95 million to $96 million, representing a growth rate of 27% to 29% on a like-for-like basis.

With that, I'll hand the call over to Troy, who will provide an overview of our full Q3 results and changes to our total guidance. Thank you, Rod. We reported Q3 revenue of $28.1 million, representing an increase of 31% year-over-year. The year-over-year increase was primarily related to a 33% increase in our cell processing platform, driven by strong demand from biopreservation media customers with commercially approved therapies. In addition, Q3 included a biopreservation media sales order of approximately $1.3 million that was anticipated to ship in Q4, but based on the customer's request was shipped in Q3. GAAP gross margin for Q3 2025 was 62% compared with 63% in Q3 2024. Adjusted gross margin for the third quarter was 64% compared with 67% in the prior year. The decrease in adjusted gross margin percentage compared with the prior year was primarily attributed to a $600,000 one-time inventory reserve we took in Q3 2025, which represented approximately 2% of our Q3 2025 revenue. Additionally, there was a less favorable product mix compared to the prior year. GAAP operating expenses for Q3 2025 were $28.2 million versus $21.8 million in Q3 2024. The increase compared to the prior year can be attributed to increases in cost of sales related to our increased revenues and an increase in stock-based compensation expense of $1.8 million over Q3 2024 related to performance-based awards. Adjusted operating expenses for Q3 2025 totaled $16.6 million compared with $14.1 million in the prior year. GAAP operating loss for Q3 2025 was $89,000 versus $418,000 in the prior year. The decrease in GAAP operating loss was primarily due to increased revenue compared to the prior year. Our adjusted operating income for the third quarter of 2025 was $1.3 million compared with an adjusted operating income of $167,000 in Q3 2024. Our GAAP net income was $621,000 or $0.01 per share in Q3 compared to GAAP net loss of $471,000 or $0.01 per share in the prior year. The increase in net income was primarily due to increased revenues compared to the prior year. Adjusted EBITDA for the third quarter of 2025 was $7.8 million or 28% of revenue compared with $5 million or 23% of revenue in the prior year. Adjusted EBITDA increased from the prior year, primarily due to a $3.9 million increase in gross margin, driven by increased sales of biopreservation media and includes a $600,000 one-time inventory reserve. Turning to our balance sheet. Our cash and marketable securities balance reported as of September 30, 2025, was $98.4 million compared with $100.2 million as of June 30, 2025. Taking into consideration our adjusted EBITDA of $7.8 million in Q3, cash usage was primarily driven by capital expenditures of $3.7 million, debt principal payments of $2.5 million and the purchase of the Pluristyx convertible promissory note for $2 million. The September balance excludes the proceeds from the sale of our evo Cold Chain logistics product line, which occurred on October 6. The entirety of our $7.5 million SVB debt balance is considered short-term. Our final payment on the SVB debt balance is due June 2026. We continue to expect making quarterly repayments of $2.5 million and have a $1.2 million loan maturity balloon payment due at the time of maturity. Subsequent to quarter end, on October 6, we completed the sale of our evo Cold Chain logistics subsidiary for an aggregate sales price of $25.5 million, subject to certain adjustments. In our Q3 earnings release, we are presenting an estimate of key financial results, excluding evo by quarter for 2024 through Q3 2025. Turning to our 2025 financial guidance. We are increasing our original guidance from our Q2 earnings call, and we are adjusting our full year guidance to reflect the divestiture of the evo Cold Chain logistics business, which occurred on October 6, and we anticipate will be classified as discontinued operations. Our previously stated revenue guidance from the Q2 earnings call was $100 million to $103 million, which included approximately $8 million of revenue attributed to evo. Adjusting for evo, our total revenue guidance would have been $92 million to $95 million. We are now raising our adjusted 2025 total revenue guidance to $95 million to $96 million, which includes our cell processing and ThawSTAR product lines, representing an increase of 27% to 29% when compared to prior year revenue on a like-for-like basis. Our adjusted revenue guidance includes increasing our cell processing revenue guidance from $91 million to $93 million, to $93 million to $94 million or a 26% to 28% growth rate compared to prior year. Our guidance implies a sequential decrease in revenue in Q4 compared to Q3 due to the $1.3 million media order that was anticipated to take place in Q4, but based on the customer's request was shipped in Q3. We continue to expect adjusted gross margin for the full year to be in the mid-60s, a reduction of GAAP net loss and expansion in adjusted EBITDA margin in 2025 when compared to 2024 due to higher expected revenue, partially offset by increases in R&D expenses related to development projects. Finally, in terms of our share count, as of October 30, we had 48.1 million shares issued and outstanding and 50.1 million shares on a fully diluted basis. Now I'll turn the call back to the operator to open up for questions.

Operator Instructions] And our first question will come from Paul Knight with KeyBanc.

Congrats on the quarter. What's pricing like? What was it in 3 or 9 months year-to-date? And what do you anticipate pricing to be in the years ahead?

I'll take the last part and let Troy address the first one. So, we're expecting to increase prices in '26 between 4% and 6% depending on the SKU.

If you're talking about price growth in year-to-date Q3, we did have price growth that was higher than our list price increases due to those customer contract negotiations we've been talking about.

On your direct sales, I know you're trying to sell a variety of products now. What have you been doing with headcount, non-media sales? Could you give us color about do you continue to increase that direct sales level in the future quite a bit? Where are you with headcount to give us a gauge of kind of what your efforts are maybe headcount versus a year ago on direct sales?

We've added one team focused on cross-selling opportunities, bringing the total to about six. However, until we have more confidence in the return on that investment, we will hold off on expanding further, although I do expect more additions in 2026. Our primary focus will be on the top 20 direct customers who are most likely to adopt additional technologies. The numbers are relatively small. The sales team is also engaging with about 30% of biopreservation media clinical trials where we are not clearly specified. We might already be included in some of those, but it's difficult for us to determine our role. Looking at the clinical pipeline of our core direct customers with commercial therapies available, which includes about half a dozen, their pipelines are quite strong. Our goal is to encourage these customers to adopt our key products: CryoCase, CellSeal, HPL, and CT5.

Our next question will come from Matt Stanton. Just one second. Matt Stanton?

Rod, maybe one for you. Just in terms of what you saw in 3Q, obviously, it sounds like the commercial was chugging along nicely. Would love to just get a little bit more color. It sounds like trends were solid across the broader cell processing tools portfolio, albeit that's a smaller piece. And then just curious on the clinical side. We've seen a couple of months here of a little bit better biotech funding, but would love a little more color on what your discussions are like there as well.

Overall, we experienced growth across various customer segments, although the rates of growth varied significantly. Our core commercial customers are the main contributors to this growth in terms of their year-over-year growth rate. We maintain regular communication with our key distributors. According to our latest quarterly business review with our largest distributor, who may be more affected by funding issues, they haven't identified any specific factors, positive or negative, that would clarify the progress they are observing this year. They aren't raising concerns, nor are they indicating that everything is fine, so we remain in a wait-and-see position. We haven't noticed specific impacts from the government shutdown, but if there are any, it would likely be a minor amount of revenue anticipated in the fourth quarter, which we have already factored into our guidance for the year.

And then maybe just taking a step back and thinking about the framing around '26. I know it's early days, but you have evo gone. I think the rest of the portfolio, you have pretty good visibility. And if we start to think about '26, you'll have a tougher comp relative to this year. It sounds like there's been nice pricing this year, but you also expect to take pricing next year. Just can you help kind of help us frame how you're thinking about '26?

I'll do it qualitatively, Matt. We believe we've got really strong momentum going into '26. We expect that a lot of the growth in '26 that we're going to realize will be driven by those commercial customers. But we do expect to see growth across all of our customer segments in the year. We're expecting to receive the full '26 forecast from these large customers in January. And that's a key part of our methodology relative to developing guidance. And so, we're going to have that by the end of January so that we'll be ready to provide very specific guidance, which is based on some pretty good visibility on our FY '25 call in mid-February.

And our next question will come from Mac Etoc with Stephens.

I'll add my congrats as well. Maybe just a few for me. Now that the evo platform has gone and kind of removed from numbers, do you anticipate any lingering costs in Q4 and into FY '26? And then secondly, this is essentially the last piece of the strategic review puzzle that's now complete. So, what are you thinking in terms of capital allocation with the cash that you have on your balance sheet?

Troy, do you want to take the first one?

Regarding your question about any residual costs in Q4, if you refer to the earnings release, we have provided an estimate of our financial results excluding evo. Therefore, the Q3 number serves as a solid baseline for Q4 as well. Currently, there are no lingering operating expenses in our corporate structure. What we presented in the earnings release is our current outlook.

In response to your question about capital allocation, Mac, we are definitely keen on exploring opportunities related to both our current product line and other areas that align with our core strengths. We're planning to be more proactive in this exploration in 2026 now that the strategic transformation work is completed. This aligns with creating our own three-year product roadmap based on the technology we currently possess. However, I want to emphasize that we will take a disciplined approach to our evaluations. A crucial criterion for us regarding any inorganic opportunities is ensuring there is no negative impact, or at least no materially negative impact, on our financial profile. While there are potential assets that could align with us, this criterion may disqualify some deals. I'm quite firm about maintaining our financial profile. We have made substantial progress, and I believe we have significant margin expansion opportunities ahead, and I do not want to hinder that in any way.

Our next question comes from Brendan Smith with TD Cowen.

Nice to see the steady demand across the segment and the new guidance, too. I kind of just piggybacking on some of the earlier questions here. Just trying to get a little bit better sense for the really next wave of growth for you all. I guess in conversations with customers, how are you kind of feeling like a potentially more stable funding environment for pharma and biotech might impact their risk appetite to either expand some of these use cases for CNGT or even maybe rotate out of these modalities altogether? Just kind of trying to understand some of the puts and takes for maybe the next 18 to 24 months.

Our commercial and late-stage clinical customers contribute over 50% of our BPM revenue, and we anticipate this contribution will continue to grow and accelerate. This is what we are counting on for our growth over the next 18 to 24 months. While we believe that other areas will grow, the stronger growth rate will primarily come from these customers. The positive aspect is that many of our commercial customers have a substantial clinical pipeline. We are currently involved in 30 Phase III clinical trials, and we expect that a significant number of these will make progress in the next 24 months, adding to the growth from our existing commercial therapies.

Operator Instructions] Our next question comes from Thomas Flaten with Lake Street.

Rod, on some prior calls, there had been some discussion around you had a customer evaluating the CryoCase. Any update on how that project is going?

Yes, it's going. I think we're getting closer to a point where we're getting them to make a commitment to us in exchange, as I've talked about before, for doing some development work. We're not going to do the development work on the come per se. But these are large organizations. They've got a lot of things going on. The good news is that, again, deep clinical pipeline, we're not going to be in their commercial therapy, which is going great guns. But they definitely have a pain point on bags. They've expressed that to us a number of times. So, it's really our product development team working with their process development folks about exactly what changes they want made. I think we're pretty close to that part. And now it's really coming down to the more commercial discussion of, okay, what level of commitment can you make to us for us to go ahead and expand the resources to make this happen. And we could, of course, do it just on the come, but I think it's important to solidify their commitment to adopting the technology into their clinical pipeline before we start spending money on it.

And then just to follow up on a prior question regarding the strategic review process being complete. So Thaw is with us, right? Thaw is not going anywhere. That was never on the table, just to confirm?

It was never considered. We believe that Thaw functions more like a reverse razor-razor blade type of product. Over the past year and a half, we successfully adapted the Thaw unit to work with CellSeal vials, which are a different size. The Thaw vial device was originally designed for thawing. We are currently working on adapting it for our CryoCase to create an automated Thaw device for that product. This system is highly complementary to the two products. It maintains good profit margins, requires minimal sales and marketing efforts on our part at this stage, and still achieves consistent growth at an appealing rate. So, it's certainly worth keeping.

There's no further questions, this will conclude the question-and-answer session. I would like to turn the conference back over to Roderick de Greef, CEO and Chairman of the Board, for any closing remarks.

Thank you, Wyatt. In closing, it's been 2 years since I returned to the company in an operating role. As I look back, I'm very pleased with the progress the BioLife team has made in executing a fundamental strategic transformation. In the last 24 months, we have solidified and built upon our market leadership position in biopreservation media, driving strong top line growth and significant margin expansion. We have optimized our product portfolio so that we can focus our efforts on our higher growth and higher margin recurring revenue products. We have also strengthened our balance sheet and have the resources to explore inorganic product portfolio expansion into relevant adjacencies in a measured and disciplined manner. All of this, in combination with what is still a relatively nascent but very exciting market, leaves us confident in our ability to continue to deliver sustainable revenue growth, margin expansion, and shareholder value creation in 2026 and beyond. Thank you for your time today, and I look forward to seeing some of you at upcoming investor conferences.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.